11 completed, 1 withdrawn. 12 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 12 | Completed 11, Withdrawn 1 |
| Phase 2 | 1 | Completed 1 |
Follow Medroxyprogesterone: new trials by email Literature Review of Medroxyprogesterone trials Research Report on Medroxyprogesterone
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Live Birth Rate Between PPOS and GnRH Antagonist Protocol in Patients With Anticipated High Ovarian Response Progesterone, GnRH Antagonist - IVF, GnRH Antagonist | Phase 3 | Completed | ShangHai Ji Ai Genetics & IVF Institute | 784 | 2020-06-04 | 2023-08-30 |
| Hormone Replacement for Premature Ovarian Insufficiency Hormone Replacement Therapy, Combined Oral Contraceptives - Primary Ovarian Insufficiency | Phase 3 | Withdrawn | University of Pennsylvania | 2016-03-01 | 2019-07-05 | |
| Medroxyprogesterone Compared With Venlafaxine in Treating Hot Flashes in Women medroxyprogesterone, venlafaxine - Hot Flashes | Phase 3 | Completed | Alliance for Clinical Trials in Oncology | 227 | 2002-04-01 | 2016-07-13 |
| Alzheimer's Disease: Therapeutic Potential of Estrogen Transdermal estradiol, Medroxyprogesterone, Placebo Patch - Alzheimer Disease | Phase 2 / Phase 3 | Completed | University of Wisconsin, Madison | 42 | 2001-09-01 | 2018-08-23 |
| Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast Cancer conjugated estrogens, medroxyprogesterone - Breast Cancer, Hot Flashes | Phase 3 | Completed | Eastern Cooperative Oncology Group | 2000-11-28 | 2023-06-15 | |
| S9630, Medroxyprogesterone in Treating Women With Breast Cancer medroxyprogesterone, tamoxifen citrate, adjuvant therapy - Breast Cancer, Endometrial Cancer | Phase 3 | Completed | SWOG Cancer Research Network | 313 | 1997-03-01 | 2012-10-31 |
| Estrogen and Graft Atherosclerosis Research Trial (EAGER) hormone replacement therapy, estrogens, medroxyprogesterone - Cardiovascular Diseases, Coronary Arteriosclerosis | Phase 3 | Completed | National Heart, Lung, and Blood Institute (NHLBI) | 1996-08-01 | 2016-02-18 | |
| Women's Estrogen/Progestin Lipid Lowering Hormone Atherosclerosis Regression Trial (WELL-HART) estrogen replacement therapy, hormone replacement therapy, estradiol - Cardiovascular Diseases, Coronary Disease | Phase 3 | Completed | National Heart, Lung, and Blood Institute (NHLBI) | 1995-03-01 | 2016-07-12 | |
| Phase III Randomized Study of the Effect of Postmenopausal Estrogen Replacement Therapy on Alveolar Bone Loss conjugated estrogens, Medroxyprogesterone - Osteoporosis | Phase 3 | Completed | National Institute of Dental and Craniofacial Research (NIDCR) | 150 | 1993-08-01 | 2005-06-24 |
| Heart and Estrogen-Progestin Replacement Study (HERS) Premarin .625 mg daily plus medroxyprogesterone 2.5 mg daily - Coronary Heart Disease | Phase 3 | Completed | University of California, San Francisco | 2430 | 1992-07-01 | 2006-04-27 |
| Postmenopausal Estrogen/Progestin Interventions (PEPI) estrogens, conjugated, medroxyprogesterone, progesterone - Bone Diseases, Cardiovascular Diseases | Phase 3 | Completed | National Heart, Lung, and Blood Institute (NHLBI) | 1987-09-01 | 2016-05-13 | |
| Medroxyprogesterone or Interferon and/or Aldesleukin in Treating Patients With Metastatic Kidney Cancer aldesleukin, recombinant interferon alpha-2a, medroxyprogesterone - Kidney Cancer | Phase 3 | Completed | Centre Leon Berard | 456 | 2012-09-26 |
Coronary Disease (4) · Cardiovascular Diseases (3) · Heart Diseases (3) · Myocardial Ischemia (3) · Breast Carcinoma In Situ (2) · Breast Neoplasms (2) · Hot Flashes (2) · Osteoporosis (2) · Alzheimer Disease (1) · Bone Diseases (1) · Carcinoma, Ductal, Breast (1) · Carcinoma, Intraductal, Noninfiltrating (1) · Carcinoma, Renal Cell (1) · Coronary Artery Disease (1) · Diabetes Mellitus (1)
National Heart, Lung, and Blood Institute (NHLBI) (3) · Alliance for Clinical Trials in Oncology (1) · Centre Leon Berard (1) · Eastern Cooperative Oncology Group (1) · National Institute of Dental and Craniofacial Research (NIDCR) (1) · SWOG Cancer Research Network (1) · ShangHai Ji Ai Genetics & IVF Institute (1) · University of California, San Francisco (1) · University of Pennsylvania (1) · University of Wisconsin, Madison (1)
United States (6) · China (1)
Barbara L. Smith, MD, PhD (1) · Charles F. Hildebolt (1) · Charles L. Loprinzi, MD (1) · Howard Hodis (1) · Mark Espeland (1) · Melody A. Cobleigh, MD (1) · Pamela Ouyang (1) · Ronald K. Potkul, MD (1) · Sanjay Asthana, MD (1) · Stephen Hulley (1) · Sylvie Negrier, MD (1)
PMID 16505409, PMID 17329508, PMID 17932908, PMID 38272383
R01AG017196 (1), U01HL040232 (1), U01HL050840 (1), U10CA032102 (1), U10CA037429 (1)